Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.
Twelve hypertensive patients received oral labetalol treatment (average final dose 1,200 mg/d) over a period of 16 months. 2 Satisfactory blood pressure control was maintained both at rest and after exercise. 3 Plasma renin activity was significantly reduced. 4 Postural hypotension measured in this group of patients after a single dose of labetalol 50 mg intravenously was considerably reduced during long-term oral treatment. 5 No serious side-effects were observed nor were there any significant changes in haematological and biochemical variables during the period. 6 Haemodynamic data obtained in two of the patients after 16 months' treatment suggests that the haemodynamic profile observed after acute intravenous administration is maintained after prolonged oral treatment.
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D007741:Labetalol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D011674:Pulse / Q000187:drug effects; D012083:Renin / Q000097:blood
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D012083:Renin; D007741:Labetalol